The pipeline of next-generation treatments is advancing rapidly: Novo Nordisks CagriSema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide, has an FDA decision expected in late 2026 and could further accelerate the market
Each method offers unique benefits and considerations based on patient needs, absorption capabilities, and treatment goals
They do not establish that KPV treats Crohns disease, ulcerative colitis, irritable bowel syndrome or intestinal permeability disorders
These medications add another layer of support by working on the underlying systems that influence weight, making it easier to see meaningful, lasting progress
Viswanathan, V.S., Ryan, M.J., Dhruv, H.D., et al
GLP-1 receptor agonists mimic the GLP-1 peptide that's made by your body naturally